Genmab’s Revenue Soars with Strategic Developments
Company Announcements

Genmab’s Revenue Soars with Strategic Developments

Genmab (GMAB) has released an update.

Genmab’s revenue surged by 29% in the first nine months of 2024, reaching DKK 15,085 million, primarily driven by increased royalties from its collaborations and strong sales of its cancer treatments. The company received conditional marketing authorization in Europe for TEPKINLY®, expanding its portfolio and signaling growth potential. Genmab’s updated financial guidance reflects a robust performance, though it remains focused on disciplined investment strategies.

For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskGenmab Reports Strong Growth and Strategic Advances
TipRanks Auto-Generated NewsdeskGenmab Sees Strong DARZALEX Sales in Q3 2024
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App